CleftGeneDB-Search

Gene: SMAD2

Basic information

Tag	Content
Uniprot ID	Q15796
Entrez ID	4087
Genbank protein ID	AAC50789.1; AAH25699.1; AAC51918.1; AAB17087.1; AAB17054.1; AAC39657.1; AAH14840.1;
Genbank nucleotide ID	XM_006722451.3; NM_005901.5; XM_017025745.1; XM_017025746.1; XM_005258259.3; NM_001003652.3;
Ensembl protein ID	ENSP00000349282; ENSP00000384449; ENSP00000262160; ENSP00000466193;
Ensembl nucleotide ID	ENSG00000175387
Gene name	Mothers against decapentaplegic homolog 2
Gene symbol	SMAD2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Manually collected
Reference	17564975
Functional description	Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD2/SMAD4 complex, activates transcription. May act as a tumor suppressor in colorectal carcinoma. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.
Sequence	MSSILPFTPP VVKRLLGWKK SAGGSGGAGG GEQNGQEEKW CEKAVKSLVK KLKKTGRLDE 60 LEKAITTQNC NTKCVTIPST CSEIWGLSTP NTIDQWDTTG LYSFSEQTRS LDGRLQVSHR 120 KGLPHVIYCR LWRWPDLHSH HELKAIENCE YAFNLKKDEV CVNPYHYQRV ETPVLPPVLV 180 PRHTEILTEL PPLDDYTHSI PENTNFPAGI EPQSNYIPET PPPGYISEDG ETSDQQLNQS 240 MDTGSPAELS PTTLSPVNHS LDLQPVTYSE PAFWCSIAYY ELNQRVGETF HASQPSLTVD 300 GFTDPSNSER FCLGLLSNVN RNATVEMTRR HIGRGVRLYY IGGEVFAECL SDSAIFVQSP 360 NCNQRYGWHP ATVCKIPPGC NLKIFNNQEF AALLAQSVNQ GFEAVYQLTR MCTIRMSFVK 420 GWGAEYRRQT VTSTPCWIEL HLNGPLQWLD KVLTQMGSPS VRCSSMS 467

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1DEV
1KHX
1U7V
2LB3
5XOD
5ZOJ
1DEV
1KHX

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Developmental stage	Species	Evidence	Details
1:1 ortholog	SMAD2		E1BE92		Bos taurus	Prediction	More>>
1:1 ortholog	SMAD2	480144	A0A5F4DFT1		Canis lupus familiaris	Prediction	More>>
1:1 ortholog	SMAD2	102188455	A0A452FCX6		Capra hircus	Prediction	More>>
1:1 ortholog	SMAD2	4087	Q15796		Homo sapiens	Publication	More>>
1:1 ortholog	Smad2	17126	Q62432	E12.0, E12.5, E13.0, E13.5, E14.0, E15.0, E14.5	Mus musculus	Prediction	More>>
1:1 ortholog	SMAD2	455407	H2QEH9		Pan troglodytes	Prediction	More>>
1:1 ortholog	SMAD2	100155304	A0A287AE86		Sus scrofa	Prediction	More>>
1:1 ortholog	SMAD2	100359137	G1T109		Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Smad2	29357	O70436		Rattus norvegicus	Prediction	More>>
1:1 ortholog	smad2		F1Q5P5		Danio rerio	Prediction	More>>

Identified variants/mutations related to cleft phenotype

Gene symbol	Significant Variants/SNPS	Methods	PubMed ID
SMAD2	rs728683	Genome wide linkage analysis	17564975

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1341462958	p.Thr8Met	missense variant	-	NC_000018.10:g.47896734G>A	gnomAD
rs749758342	p.Pro9Leu	missense variant	-	NC_000018.10:g.47896731G>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Leu16Val	missense variant	-	NC_000018.10:g.47896711G>C	NCI-TCGA
RCV000578545	p.Trp18Ter	nonsense	-	NC_000018.10:g.47896704C>T	ClinVar
rs1555658568	p.Trp18Ter	stop gained	-	NC_000018.10:g.47896704C>T	-
rs747301606	p.Gly24Arg	missense variant	-	NC_000018.10:g.47896687C>G	ExAC
rs143058641	p.Ser25Cys	missense variant	-	NC_000018.10:g.47896683G>C	ESP,ExAC,TOPMed,gnomAD
rs1186363719	p.Gly27Glu	missense variant	-	NC_000018.10:g.47896677C>T	gnomAD
rs1239673820	p.Gly30Val	missense variant	-	NC_000018.10:g.47896668C>A	TOPMed
rs1239631809	p.Asn34Ile	missense variant	-	NC_000018.10:g.47896656T>A	gnomAD
rs1178643701	p.Lys39Arg	missense variant	-	NC_000018.10:g.47896641T>C	gnomAD
NCI-TCGA novel	p.Glu42TyrAsnArgMetGlnValSerTer	stop gained	-	NC_000018.10:g.47896631_47896632insTAACTTACTTGCATCCTGTTATAT	NCI-TCGA
rs1456954386	p.Ala44Thr	missense variant	-	NC_000018.10:g.47896627C>T	gnomAD
COSM3821518	p.Lys53Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47896598C>A	NCI-TCGA Cosmic
rs1445838443	p.Lys54Ile	missense variant	-	NC_000018.10:g.47896596T>A	gnomAD
NCI-TCGA novel	p.Thr55Ala	missense variant	-	NC_000018.10:g.47896594T>C	NCI-TCGA
COSM4869360	p.Arg57Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47896587C>T	NCI-TCGA Cosmic
RCV000494088	p.Leu58Ter	nonsense	-	NC_000018.10:g.47896584A>T	ClinVar
rs1131691755	p.Leu58Ter	stop gained	-	NC_000018.10:g.47896584A>T	-
rs375368905	p.Asp59Glu	missense variant	-	NC_000018.10:g.47896580A>T	ESP,ExAC,gnomAD
NCI-TCGA novel	p.Lys63Gln	missense variant	-	NC_000018.10:g.47896570T>G	NCI-TCGA
NCI-TCGA novel	p.Ala64Val	missense variant	-	NC_000018.10:g.47896566G>A	NCI-TCGA
rs1242869146	p.Ile65Val	missense variant	-	NC_000018.10:g.47896564T>C	gnomAD
COSM3970568	p.Thr72Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47896543T>C	NCI-TCGA Cosmic
rs1374795369	p.Thr76Ala	missense variant	-	NC_000018.10:g.47896531T>C	gnomAD
rs1326742866	p.Ile77Lys	missense variant	-	NC_000018.10:g.47896527A>T	gnomAD
rs761359766	p.Pro78Gln	missense variant	-	NC_000018.10:g.47896524G>T	ExAC,gnomAD
rs908853616	p.Cys81Phe	missense variant	-	NC_000018.10:g.47870559C>A	TOPMed,gnomAD
COSM4480835	p.Ser82Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47870556G>C	NCI-TCGA Cosmic
rs1418778323	p.Ile84Phe	missense variant	-	NC_000018.10:g.47870551T>A	gnomAD
rs779006352	p.Leu87Pro	missense variant	-	NC_000018.10:g.47870541A>G	ExAC,TOPMed,gnomAD
rs1173764083	p.Ser88Asn	missense variant	-	NC_000018.10:g.47870538C>T	gnomAD
rs756023240	p.Pro90Ser	missense variant	-	NC_000018.10:g.47870533G>A	ExAC,gnomAD
rs756023240	p.Pro90Thr	missense variant	-	NC_000018.10:g.47870533G>T	ExAC,gnomAD
rs750419429	p.Asn91Asp	missense variant	-	NC_000018.10:g.47870530T>C	ExAC,gnomAD
rs984513669	p.Thr92Met	missense variant	-	NC_000018.10:g.47870526G>A	gnomAD
rs984513669	p.Thr92Arg	missense variant	-	NC_000018.10:g.47870526G>C	gnomAD
rs780848010	p.Asp94Asn	missense variant	-	NC_000018.10:g.47870521C>T	ExAC,gnomAD
NCI-TCGA novel	p.Gln95His	missense variant	-	NC_000018.10:g.47870516C>A	NCI-TCGA
rs1445556377	p.Gln95Arg	missense variant	-	NC_000018.10:g.47870517T>C	gnomAD
rs757084234	p.Gln95Glu	missense variant	-	NC_000018.10:g.47870518G>C	ExAC,gnomAD
rs1204906548	p.Thr98Ala	missense variant	-	NC_000018.10:g.47870509T>C	TOPMed
rs1312562947	p.Thr98Ile	missense variant	-	NC_000018.10:g.47870508G>A	gnomAD
rs1234431657	p.Gly100Asp	missense variant	-	NC_000018.10:g.47870502C>T	TOPMed
NCI-TCGA novel	p.Ser103Ile	missense variant	-	NC_000018.10:g.47870493C>A	NCI-TCGA
rs763832609	p.Phe104Leu	missense variant	-	NC_000018.10:g.47870491A>G	ExAC,gnomAD
rs762509218	p.Gln107Arg	missense variant	-	NC_000018.10:g.47870481T>C	ExAC,gnomAD
rs752221087	p.Thr108Ile	missense variant	-	NC_000018.10:g.47870478G>A	ExAC,gnomAD
rs1404495202	p.Arg114His	missense variant	-	NC_000018.10:g.47869422C>T	TOPMed
rs1458298591	p.Arg114Gly	missense variant	-	NC_000018.10:g.47869423G>C	gnomAD
rs767928066	p.Ser118Cys	missense variant	-	NC_000018.10:g.47869410G>C	ExAC,gnomAD
rs1452605724	p.His119Arg	missense variant	-	NC_000018.10:g.47869407T>C	TOPMed
NCI-TCGA novel	p.Arg120Ter	stop gained	-	NC_000018.10:g.47869405G>A	NCI-TCGA
rs374809046	p.Arg120Gln	missense variant	-	NC_000018.10:g.47869404C>T	ESP,ExAC,gnomAD
NCI-TCGA novel	p.Gly122Ter	stop gained	-	NC_000018.10:g.47869399C>A	NCI-TCGA
COSM473873	p.Gly122Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47869398C>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Pro124Thr	missense variant	-	NC_000018.10:g.47869393G>T	NCI-TCGA
rs746965273	p.Ile127Met	missense variant	-	NC_000018.10:g.47869382T>C	ExAC,gnomAD
COSM6023533	p.Arg130Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000018.10:g.47869375G>A	NCI-TCGA Cosmic
rs372254986	p.Arg130Gln	missense variant	-	NC_000018.10:g.47869374C>T	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Arg133His	missense variant	-	NC_000018.10:g.47869365C>T	NCI-TCGA
COSM3378505	p.Arg133Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47869366G>A	NCI-TCGA Cosmic
VAR_011375	p.Arg133Cys	Missense	-	-	UniProt
rs1267982516	p.Trp134Ter	stop gained	-	NC_000018.10:g.47869361C>T	TOPMed
rs1405142772	p.Pro135Ser	missense variant	-	NC_000018.10:g.47869360G>A	gnomAD
COSM4072376	p.Asp136Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47869356T>A	NCI-TCGA Cosmic
rs749306809	p.His141Gln	missense variant	-	NC_000018.10:g.47869340A>T	ExAC,TOPMed,gnomAD
COSM1226714	p.Glu142Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000018.10:g.47869339C>A	NCI-TCGA Cosmic
rs753418067	p.Lys144Arg	missense variant	-	NC_000018.10:g.47869332T>C	ExAC,TOPMed,gnomAD
rs753418067	p.Lys144Thr	missense variant	-	NC_000018.10:g.47869332T>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ala145Thr	missense variant	-	NC_000018.10:g.47869330C>T	NCI-TCGA
rs765857326	p.Ala145Val	missense variant	-	NC_000018.10:g.47869329G>A	ExAC,gnomAD
rs368541611	p.Ile146Val	missense variant	-	NC_000018.10:g.47869327T>C	ESP
rs756633093	p.Ile146Met	missense variant	-	NC_000018.10:g.47869325A>C	ExAC,TOPMed,gnomAD
COSM4072374	p.Cys149Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47869317C>T	NCI-TCGA Cosmic
rs200841904	p.Glu150Lys	missense variant	-	NC_000018.10:g.47869315C>T	TOPMed,gnomAD
NCI-TCGA novel	p.Phe153Val	missense variant	-	NC_000018.10:g.47869306A>C	NCI-TCGA
COSM3526089	p.Lys156Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47869297T>C	NCI-TCGA Cosmic
NCI-TCGA novel	p.Lys157Thr	missense variant	-	NC_000018.10:g.47869293T>G	NCI-TCGA
rs750959440	p.Lys157Arg	missense variant	-	NC_000018.10:g.47869293T>C	ExAC,gnomAD
RCV000480930	p.Glu159Ter	nonsense	-	NC_000018.10:g.47869288C>A	ClinVar
COSM4874108	p.Glu159Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47869286T>G	NCI-TCGA Cosmic
rs1064793873	p.Glu159Ter	stop gained	-	NC_000018.10:g.47869288C>A	-
COSM4072372	p.Tyr165Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000018.10:g.47869268G>C	NCI-TCGA Cosmic
rs1221585986	p.Glu171Gln	missense variant	-	NC_000018.10:g.47869252C>G	gnomAD
rs1404671002	p.Pro173Ser	missense variant	-	NC_000018.10:g.47869246G>A	gnomAD
NCI-TCGA novel	p.Pro176Arg	missense variant	-	NC_000018.10:g.47868451G>C	NCI-TCGA
rs1260546123	p.Pro176Leu	missense variant	-	NC_000018.10:g.47868451G>A	gnomAD
rs751894908	p.Pro177Gln	missense variant	-	NC_000018.10:g.47868448G>T	ExAC
rs1397643390	p.Val180Met	missense variant	-	NC_000018.10:g.47868440C>T	gnomAD
NCI-TCGA novel	p.Pro181Leu	missense variant	-	NC_000018.10:g.47868436G>A	NCI-TCGA
rs1474511926	p.Pro181Arg	missense variant	-	NC_000018.10:g.47868436G>C	gnomAD
rs370352616	p.Arg182Gly	missense variant	-	NC_000018.10:g.47868434G>C	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Arg182AspPheSerTerUnk	frameshift	-	NC_000018.10:g.47868434G>-	NCI-TCGA
COSM3772569	p.Arg182Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000018.10:g.47868434G>A	NCI-TCGA Cosmic
rs752926868	p.Arg182Gln	missense variant	-	NC_000018.10:g.47868433C>T	ExAC
rs773233757	p.Ile186Phe	missense variant	-	NC_000018.10:g.47868422T>A	ExAC,gnomAD
rs772166220	p.Leu187Ile	missense variant	-	NC_000018.10:g.47868419G>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Thr188GlyPheSerTerUnk	frameshift	-	NC_000018.10:g.47868416_47868417insCTCC	NCI-TCGA
NCI-TCGA novel	p.Thr188IlePheSerTerUnkUnk	frameshift	-	NC_000018.10:g.47868415_47868416insAA	NCI-TCGA
NCI-TCGA novel	p.Glu189Ter	stop gained	-	NC_000018.10:g.47868413C>A	NCI-TCGA
rs761881557	p.Leu190Ile	missense variant	-	NC_000018.10:g.47868410G>T	ExAC,gnomAD
rs774275037	p.Leu190Arg	missense variant	-	NC_000018.10:g.47868409A>C	ExAC,gnomAD
rs1293658510	p.Pro191Leu	missense variant	-	NC_000018.10:g.47868406G>A	TOPMed,gnomAD
rs1400171724	p.Thr197Asn	missense variant	-	NC_000018.10:g.47868388G>T	TOPMed
COSM4871329	p.His198Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47868386G>A	NCI-TCGA Cosmic
rs576952880	p.Ser199Phe	missense variant	-	NC_000018.10:g.47868382G>A	1000Genomes,ExAC,gnomAD
rs1378562573	p.Ser199Thr	missense variant	-	NC_000018.10:g.47868383A>T	TOPMed
NCI-TCGA novel	p.Ser199Cys	missense variant	-	NC_000018.10:g.47868382G>C	NCI-TCGA
rs1403763933	p.Pro201Leu	missense variant	-	NC_000018.10:g.47868376G>A	gnomAD
rs745402632	p.Thr204Ala	missense variant	-	NC_000018.10:g.47868368T>C	ExAC,gnomAD
rs780724388	p.Asn205Lys	missense variant	-	NC_000018.10:g.47868363G>C	ExAC,TOPMed,gnomAD
rs780724388	p.Asn205Lys	missense variant	-	NC_000018.10:g.47868363G>T	ExAC,TOPMed,gnomAD
rs1379477222	p.Ile210Thr	missense variant	-	NC_000018.10:g.47868349A>G	TOPMed
rs1256444049	p.Pro212Ala	missense variant	-	NC_000018.10:g.47868344G>C	gnomAD
rs1229783049	p.Gln213Arg	missense variant	-	NC_000018.10:g.47868340T>C	TOPMed
rs376826930	p.Asn215Asp	missense variant	-	NC_000018.10:g.47868335T>C	ESP,ExAC,TOPMed,gnomAD
rs758691198	p.Ile217Met	missense variant	-	NC_000018.10:g.47868327A>C	ExAC,gnomAD
rs1339131203	p.Ile217Val	missense variant	-	NC_000018.10:g.47868329T>C	gnomAD
COSM988683	p.Pro221AlaPheSerTerUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000018.10:g.47865129_47865130insG	NCI-TCGA Cosmic
NCI-TCGA novel	p.Glu228Ter	stop gained	-	NC_000018.10:g.47865107C>A	NCI-TCGA
rs1230285434	p.Gln235Arg	missense variant	-	NC_000018.10:g.47865085T>C	TOPMed
rs139059864	p.Gln236His	missense variant	-	NC_000018.10:g.47865081C>A	ESP,ExAC,TOPMed,gnomAD
rs550137610	p.Leu237Phe	missense variant	-	NC_000018.10:g.47865078C>G	gnomAD
rs759180220	p.Asp242Glu	missense variant	-	NC_000018.10:g.47865063G>C	ExAC,TOPMed,gnomAD
rs781385587	p.Pro246Gln	missense variant	-	NC_000018.10:g.47851321G>T	ExAC,gnomAD
COSM3526085	p.Ser250Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47851309G>A	NCI-TCGA Cosmic
rs752743372	p.Ser250Pro	missense variant	-	NC_000018.10:g.47851310A>G	ExAC,gnomAD
rs1204398491	p.Thr252Ala	missense variant	-	NC_000018.10:g.47851304T>C	TOPMed,gnomAD
rs915038104	p.Ser255Tyr	missense variant	-	NC_000018.10:g.47851294G>T	TOPMed,gnomAD
rs369079539	p.Val257Ile	missense variant	-	NC_000018.10:g.47851289C>T	ESP,ExAC,TOPMed,gnomAD
RCV000624525	p.Asn258Ter	frameshift	Inborn genetic diseases	NC_000018.10:g.47851286dup	ClinVar
rs759337336	p.Asn258Ile	missense variant	-	NC_000018.10:g.47851285T>A	ExAC,gnomAD
rs753437227	p.Leu261Val	missense variant	-	NC_000018.10:g.47851277A>C	ExAC,gnomAD
rs369482219	p.Leu261Phe	missense variant	-	NC_000018.10:g.47851275C>G	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Asp262Tyr	missense variant	-	NC_000018.10:g.47851274C>A	NCI-TCGA
NCI-TCGA novel	p.Gln264Leu	missense variant	-	NC_000018.10:g.47848681T>A	NCI-TCGA
rs747142122	p.Val266Ala	missense variant	-	NC_000018.10:g.47848675A>G	ExAC,gnomAD
rs1224967821	p.Pro271Arg	missense variant	-	NC_000018.10:g.47848660G>C	gnomAD
rs367537998	p.Trp274Cys	missense variant	-	NC_000018.10:g.47848650C>G	-
RCV000122601	p.Trp274Cys	missense variant	-	NC_000018.10:g.47848650C>G	ClinVar
rs1226662382	p.Ser276Leu	missense variant	-	NC_000018.10:g.47848645G>A	TOPMed
rs749281211	p.Ile277Val	missense variant	-	NC_000018.10:g.47848643T>C	ExAC,gnomAD
rs779820262	p.Tyr280Cys	missense variant	-	NC_000018.10:g.47848633T>C	ExAC,gnomAD
NCI-TCGA novel	p.Glu281Ter	stop gained	-	NC_000018.10:g.47848631C>A	NCI-TCGA
rs1303977366	p.Val286Ile	missense variant	-	NC_000018.10:g.47848616C>T	gnomAD
NCI-TCGA novel	p.Ser293Leu	missense variant	-	NC_000018.10:g.47848594G>A	NCI-TCGA
rs749996078	p.Gln294Leu	missense variant	-	NC_000018.10:g.47848591T>A	ExAC,gnomAD
NCI-TCGA novel	p.Asp300Tyr	missense variant	-	NC_000018.10:g.47848574C>A	NCI-TCGA
COSM177257	p.Asp300Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47848574C>T	NCI-TCGA Cosmic
VAR_036473	p.Asp300Val	Missense	-	-	UniProt
COSM4861792	p.Gly301Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47848570C>A	NCI-TCGA Cosmic
rs574940841	p.Asp304Asn	missense variant	-	NC_000018.10:g.47848562C>T	1000Genomes
NCI-TCGA novel	p.Pro305Gln	missense variant	-	NC_000018.10:g.47848558G>T	NCI-TCGA
NCI-TCGA novel	p.Pro305Ala	missense variant	-	NC_000018.10:g.47848559G>C	NCI-TCGA
COSM256209	p.Pro305Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47848558G>A	NCI-TCGA Cosmic
rs756901143	p.Ser306Ter	stop gained	-	NC_000018.10:g.47848555G>C	ExAC,gnomAD
COSM277373	p.Asn307His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47848553T>G	NCI-TCGA Cosmic
rs1401377883	p.Asn307Asp	missense variant	-	NC_000018.10:g.47848553T>C	TOPMed,gnomAD
COSM5593210	p.Ser308Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47848549G>A	NCI-TCGA Cosmic
COSM1480353	p.Phe311Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47848539G>C	NCI-TCGA Cosmic
rs1179433290	p.Phe311Leu	missense variant	-	NC_000018.10:g.47848539G>T	TOPMed
RCV000190697	p.Cys312Ser	missense variant	Inborn genetic diseases	NC_000018.10:g.47848537C>G	ClinVar
rs797044882	p.Cys312Ser	missense variant	-	NC_000018.10:g.47848537C>G	-
NCI-TCGA novel	p.Leu315Ter	stop gained	-	NC_000018.10:g.47848528A>C	NCI-TCGA
NCI-TCGA novel	p.Leu316Phe	missense variant	-	NC_000018.10:g.47848526G>A	NCI-TCGA
COSM188749	p.Arg321Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47848510C>T	NCI-TCGA Cosmic
rs776149698	p.Arg321Ter	stop gained	-	NC_000018.10:g.47848511G>A	ExAC,gnomAD
rs765635449	p.Asn322Ser	missense variant	-	NC_000018.10:g.47848507T>C	ExAC,gnomAD
COSM4873847	p.Ala323Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47848504G>A	NCI-TCGA Cosmic
rs561086683	p.Thr324Met	missense variant	-	NC_000018.10:g.47848501G>A	1000Genomes,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Glu326Ala	missense variant	-	NC_000018.10:g.47848495T>G	NCI-TCGA
NCI-TCGA novel	p.Met327Ile	missense variant	-	NC_000018.10:g.47848491C>G	NCI-TCGA
rs1555645561	p.Ile332Thr	missense variant	-	NC_000018.10:g.47848477A>G	-
RCV000523517	p.Ile332Thr	missense variant	-	NC_000018.10:g.47848477A>G	ClinVar
COSM3692137	p.Gly335Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47845795C>T	NCI-TCGA Cosmic
COSM4865635	p.Gly335Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47845794C>T	NCI-TCGA Cosmic
rs1237400140	p.Val336Ala	missense variant	-	NC_000018.10:g.47845791A>G	TOPMed
COSM5800553	p.Arg337His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47845788C>T	NCI-TCGA Cosmic
rs1040132520	p.Arg337Cys	missense variant	-	NC_000018.10:g.47845789G>A	TOPMed
rs774455933	p.Ile341Leu	missense variant	-	NC_000018.10:g.47845777T>G	ExAC,gnomAD
NCI-TCGA novel	p.Glu344Ter	stop gained	-	NC_000018.10:g.47845768C>A	NCI-TCGA
VAR_011376	p.Glu344_Gln358del	inframe_deletion	-	-	UniProt
COSM438160	p.Phe356Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47845731A>C	NCI-TCGA Cosmic
rs1260616027	p.Val357Met	missense variant	-	NC_000018.10:g.47845729C>T	NCI-TCGA Cosmic
rs1260616027	p.Val357Met	missense variant	-	NC_000018.10:g.47845729C>T	gnomAD
COSM3796431	p.Gln364Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47845707T>G	NCI-TCGA Cosmic
rs1472524489	p.Gln364His	missense variant	-	NC_000018.10:g.47845706C>A	TOPMed
NCI-TCGA novel	p.Trp368Arg	missense variant	-	NC_000018.10:g.47845696A>G	NCI-TCGA
rs781040342	p.His369Asp	missense variant	-	NC_000018.10:g.47845693G>C	ExAC,gnomAD
rs1416015925	p.Pro370Ser	missense variant	-	NC_000018.10:g.47845690G>A	TOPMed
NCI-TCGA novel	p.Cys374Ter	frameshift	-	NC_000018.10:g.47845676_47845677AC>-	NCI-TCGA
rs1253511855	p.Lys375Arg	missense variant	-	NC_000018.10:g.47845674T>C	gnomAD
rs1228636317	p.Pro378Ser	missense variant	-	NC_000018.10:g.47845666G>A	gnomAD
NCI-TCGA novel	p.Asn386IleGlyCysAsnLeuLysIlePheAsn	insertion	-	NC_000018.10:g.47845460_47845461insTGTTGAAGATCTTCAGATTACAGCCTA	NCI-TCGA
rs746828424	p.Gln388Arg	missense variant	-	NC_000018.10:g.47845457T>C	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Phe390Cys	missense variant	-	NC_000018.10:g.47845451A>C	NCI-TCGA
rs1365824874	p.Ala392Gly	missense variant	-	NC_000018.10:g.47845445G>C	gnomAD
rs771824876	p.Leu394Met	missense variant	-	NC_000018.10:g.47845440G>T	ExAC,gnomAD
rs747866189	p.Ala395Ser	missense variant	-	NC_000018.10:g.47845437C>A	ExAC,TOPMed,gnomAD
rs1418856322	p.Gln396Leu	missense variant	-	NC_000018.10:g.47845433T>A	gnomAD
COSM3526083	p.Ser397Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47845430G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Val398Ala	missense variant	-	NC_000018.10:g.47845427A>G	NCI-TCGA
rs754313157	p.Gln400Lys	missense variant	-	NC_000018.10:g.47845422G>T	ExAC,gnomAD
rs754313157	p.Gln400Glu	missense variant	-	NC_000018.10:g.47845422G>C	ExAC,gnomAD
NCI-TCGA novel	p.Phe402LeuPheSerTerUnk	frameshift	-	NC_000018.10:g.47845414A>-	NCI-TCGA
NCI-TCGA novel	p.Phe402Cys	missense variant	-	NC_000018.10:g.47845415A>C	NCI-TCGA
rs1291358405	p.Val405Ile	missense variant	-	NC_000018.10:g.47845407C>T	gnomAD
NCI-TCGA novel	p.Tyr406LeuPheSerTerUnk	frameshift	-	NC_000018.10:g.47845403_47845404insCTTTATGTAAAATA	NCI-TCGA
COSM4859795	p.Gln407Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47845401G>C	NCI-TCGA Cosmic
rs1220285331	p.Ile414Val	missense variant	-	NC_000018.10:g.47845380T>C	gnomAD
NCI-TCGA novel	p.Arg415Ile	missense variant	-	NC_000018.10:g.47845376C>A	NCI-TCGA
NCI-TCGA novel	p.Ser417Arg	missense variant	-	NC_000018.10:g.47845371T>G	NCI-TCGA
NCI-TCGA novel	p.Gly421Ala	missense variant	-	NC_000018.10:g.47845358C>G	NCI-TCGA
COSM6082720	p.Gly421Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47845359C>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Tyr426Ter	stop gained	-	NC_000018.10:g.47845342G>T	NCI-TCGA
NCI-TCGA novel	p.Arg427Ter	missense variant	-	NC_000018.10:g.47845341G>A	NCI-TCGA
COSM1388905	p.Arg428Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47841948C>T	NCI-TCGA Cosmic
rs1420438415	p.Gln429Ter	stop gained	-	NC_000018.10:g.47841946G>A	gnomAD
rs747308534	p.Thr430Met	missense variant	-	NC_000018.10:g.47841942G>A	ExAC,TOPMed,gnomAD
COSM1471120	p.Ser433Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47841934T>C	NCI-TCGA Cosmic
rs79888759	p.Ser433Arg	missense variant	-	NC_000018.10:g.47841932A>T	ExAC,gnomAD
rs753031846	p.Thr434Ser	missense variant	-	NC_000018.10:g.47841931T>A	ExAC,gnomAD
rs1236865589	p.Pro435Ser	missense variant	-	NC_000018.10:g.47841928G>A	gnomAD
VAR_011377	p.Leu440Arg	Missense	-	-	UniProt
COSM438159	p.Leu442Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47841907G>C	NCI-TCGA Cosmic
VAR_011378	p.Pro445His	Missense	-	-	UniProt
COSM417832	p.Leu446Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47841895G>C	NCI-TCGA Cosmic
COSM6082722	p.Asp450Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47841883C>T	NCI-TCGA Cosmic
COSM6053942	p.Asp450Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47841881G>C	NCI-TCGA Cosmic
VAR_011379	p.Asp450Glu	Missense	-	-	UniProt
NCI-TCGA novel	p.Lys451Glu	missense variant	-	NC_000018.10:g.47841880T>C	NCI-TCGA
NCI-TCGA novel	p.Gln455Ter	stop gained	-	NC_000018.10:g.47841868G>A	NCI-TCGA
rs761858331	p.Met456Val	missense variant	-	NC_000018.10:g.47841865T>C	ExAC,gnomAD
NCI-TCGA novel	p.Gly457Ala	missense variant	-	NC_000018.10:g.47841861C>G	NCI-TCGA
NCI-TCGA novel	p.Cys463Ter	stop gained	-	NC_000018.10:g.47841842G>T	NCI-TCGA
NCI-TCGA novel	p.Cys463GlnPheSerTerUnkUnk	frameshift	-	NC_000018.10:g.47841841_47841844AGCA>-	NCI-TCGA
COSM268520	p.Ser464Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000018.10:g.47841840G>C	NCI-TCGA Cosmic
COSM268154	p.Ser464Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000018.10:g.47841840G>T	NCI-TCGA Cosmic
COSM5118504	p.Ser467Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000018.10:g.47841832A>G	NCI-TCGA Cosmic

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	BEFREE
C0001430	Adenoma	group	BEFREE
C0001624	Adrenal Gland Neoplasms	group	BEFREE
C0002395	Alzheimer's Disease	disease	BEFREE
C0002793	Anaplasia	disease	BEFREE
C0002940	Aneurysm	phenotype	BEFREE
C0003486	Aortic Aneurysm	disease	BEFREE
C0003850	Arteriosclerosis	disease	BEFREE
C0004096	Asthma	disease	BEFREE;LHGDN
C0004134	Ataxia	phenotype	BEFREE
C0004238	Atrial Fibrillation	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007103	Malignant neoplasm of endometrium	disease	BEFREE
C0007113	Rectal Carcinoma	disease	BEFREE
C0007114	Malignant neoplasm of skin	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE;LHGDN
C0007758	Cerebellar Ataxia	phenotype	BEFREE
C0007847	Malignant tumor of cervix	disease	BEFREE
C0007873	Uterine Cervical Neoplasm	disease	BEFREE
C0008312	Primary biliary cirrhosis	disease	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE;UNIPROT
C0009404	Colorectal Neoplasms	group	BEFREE
C0011615	Dermatitis, Atopic	disease	LHGDN
C0011644	Scleroderma	disease	BEFREE
C0011847	Diabetes	disease	BEFREE
C0011849	Diabetes Mellitus	group	BEFREE
C0014175	Endometriosis	disease	BEFREE
C0016057	Fibrosarcoma	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE;LHGDN
C0017661	IGA Glomerulonephritis	disease	BEFREE
C0018798	Congenital Heart Defects	group	BEFREE
C0018818	Ventricular Septal Defects	group	BEFREE
C0018923	Hemangiosarcoma	disease	BEFREE
C0019189	Hepatitis, Chronic	disease	CTD_human
C0019196	Hepatitis C	disease	BEFREE
C0022548	Keloid	phenotype	BEFREE
C0022577	Keratoconjunctivitis, Vernal	disease	BEFREE
C0022578	Keratoconus	disease	BEFREE
C0023267	Fibroid Tumor	group	BEFREE
C0023418	leukemia	disease	BEFREE
C0023470	Myeloid Leukemia	disease	BEFREE
C0023487	Acute Promyelocytic Leukemia	disease	BEFREE
C0023643	Lichen disease	disease	BEFREE
C0023893	Liver Cirrhosis, Experimental	disease	CTD_human
C0023903	Liver neoplasms	group	BEFREE
C0024117	Chronic Obstructive Airway Disease	disease	BEFREE
C0024121	Lung Neoplasms	group	BEFREE
C0024299	Lymphoma	group	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0024796	Marfan Syndrome	disease	CLINGEN
C0025202	melanoma	disease	BEFREE
C0025286	Meningioma	disease	BEFREE
C0026764	Multiple Myeloma	disease	LHGDN
C0027051	Myocardial Infarction	disease	BEFREE;RGD
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0028754	Obesity	disease	BEFREE
C0029172	Oral Submucous Fibrosis	disease	BEFREE
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029417	Osteoblastoma	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030193	Pain	phenotype	BEFREE
C0030297	Pancreatic Neoplasm	disease	BEFREE
C0030848	Peyronie Disease	disease	BEFREE
C0031269	Peutz-Jeghers Syndrome	disease	BEFREE
C0031511	Pheochromocytoma	disease	BEFREE
C0032584	polyps	phenotype	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE
C0033860	Psoriasis	disease	BEFREE
C0034069	Pulmonary Fibrosis	disease	BEFREE
C0035335	Retinoblastoma	disease	BEFREE
C0036421	Systemic Scleroderma	disease	BEFREE
C0037286	Skin Neoplasms	group	BEFREE
C0041956	Ureteral obstruction	phenotype	BEFREE
C0042133	Uterine Fibroids	group	BEFREE
C0042373	Vascular Diseases	group	BEFREE
C0079218	Fibromatosis, Aggressive	disease	BEFREE
C0079541	Holoprosencephaly	disease	BEFREE;GENOMICS_ENGLAND
C0085413	Polycystic Kidney, Autosomal Dominant	disease	BEFREE
C0085762	Alcohol abuse	disease	BEFREE
C0085786	Hamman-Rich syndrome	disease	BEFREE
C0149519	Chronic Persistent Hepatitis	disease	CTD_human
C0149939	Obstructive nephropathy	disease	BEFREE
C0151650	Renal fibrosis	disease	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152021	Congenital heart disease	group	BEFREE
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0162810	Cicatrix, Hypertrophic	phenotype	BEFREE
C0162872	Aortic Aneurysm, Thoracic	disease	BEFREE;GENOMICS_ENGLAND
C0178874	Tumor Progression	phenotype	BEFREE
C0235833	Congenital diaphragmatic hernia	disease	BEFREE
C0235974	Pancreatic carcinoma	disease	BEFREE
C0239946	Fibrosis, Liver	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0265287	Acromicric Dysplasia	disease	CTD_human
C0266667	Cyclocephaly	disease	BEFREE
C0278488	Carcinoma breast stage IV	disease	BEFREE
C0278701	Gastric Adenocarcinoma	disease	BEFREE
C0279607	Adult Hepatocellular Carcinoma	disease	RGD
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0280630	Uterine Carcinosarcoma	disease	BEFREE
C0302592	Cervix carcinoma	disease	BEFREE
C0340613	Arterial aneurysm	phenotype	BEFREE
C0341106	Eosinophilic esophagitis	disease	BEFREE
C0345050	Congenital aneurysm of ascending aorta	disease	GENOMICS_ENGLAND
C0345967	Malignant mesothelioma	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0346957	Disseminated Malignant Neoplasm	phenotype	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0376545	Hematologic Neoplasms	group	BEFREE
C0376634	Craniofacial Abnormalities	group	CTD_human
C0394006	Dysequilibrium syndrome	disease	BEFREE
C0424295	Hyperactive behavior	phenotype	BEFREE
C0431109	Choroid Plexus Carcinoma	disease	BEFREE
C0472767	Beta thalassemia intermedia	disease	BEFREE
C0476089	Endometrial Carcinoma	disease	BEFREE
C0520463	Chronic active hepatitis	disease	CTD_human
C0524611	Cryptogenic Chronic Hepatitis	disease	CTD_human
C0524910	Hepatitis C, Chronic	disease	BEFREE
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0600519	Ventricular Remodeling	phenotype	CTD_human
C0600520	Left Ventricle Remodeling	phenotype	CTD_human
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0685869	Monophthalmos	disease	BEFREE
C0685938	Malignant neoplasm of gastrointestinal tract	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0730328	Central Serous Chorioretinopathy	disease	BEFREE
C0879615	Stromal Neoplasm	disease	BEFREE
C0919267	ovarian neoplasm	disease	BEFREE
C0950123	Genetic Diseases, Inborn	group	CLINVAR
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1261473	Sarcoma	group	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1319315	Adenocarcinoma of large intestine	disease	BEFREE
C1321551	Shprintzen-Goldberg syndrome	disease	BEFREE
C1333990	Hereditary Nonpolyposis Colorectal Cancer	disease	BEFREE
C1335302	Pancreatic Ductal Adenocarcinoma	disease	BEFREE
C1397307	Cardiac fibrosis	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;LHGDN
C1512409	Hepatocarcinogenesis	disease	BEFREE
C1519346	Skin Carcinogenesis	disease	BEFREE
C1519670	Tumor Angiogenesis	phenotype	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE;UNIPROT
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1704376	Uterine Corpus Carcinosarcoma	disease	BEFREE
C1800706	Idiopathic Pulmonary Fibrosis	disease	BEFREE
C1876165	Copper-Overload Cirrhosis	disease	CTD_human
C1883486	Uterine Corpus Cancer	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE;LHGDN
C3203102	Idiopathic pulmonary arterial hypertension	disease	BEFREE
C3489726	Geleophysic dysplasia	disease	BEFREE;CTD_human
C3539878	Triple Negative Breast Neoplasms	disease	BEFREE
C3888391	Nonnuclear polymorphic congenital cataract	disease	BEFREE
C4020848	Aneurysmal disease	disease	BEFREE
C4048328	cervical cancer	disease	BEFREE
C4082937	Necrotizing enterocolitis in fetus OR newborn	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0000978	RNA polymerase II cis-regulatory region sequence-specific DNA binding	IDA
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	ISA
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	ISM
GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific	ISS
GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific	IDA
GO:0003682	chromatin binding	IEA
GO:0003690	double-stranded DNA binding	ISS
GO:0003700	DNA-binding transcription factor activity	IDA
GO:0005160	transforming growth factor beta receptor binding	IPI
GO:0005515	protein binding	IPI
GO:0008134	transcription factor binding	IPI
GO:0019902	phosphatase binding	IPI
GO:0030618	transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity	IDA
GO:0031625	ubiquitin protein ligase binding	IPI
GO:0033613	activating transcription factor binding	IPI
GO:0034713	type I transforming growth factor beta receptor binding	IPI
GO:0035326	cis-regulatory region binding	IC
GO:0046332	SMAD binding	IPI
GO:0046872	metal ion binding	IEA
GO:0048156	tau protein binding	ISS
GO:0070410	co-SMAD binding	IPI
GO:0070411	I-SMAD binding	IPI
GO:0070412	R-SMAD binding	IPI
GO:0070878	primary miRNA binding	IPI
GO:0097718	disordered domain specific binding	IPI
GO:0003677	DNA binding	IDA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000122	negative regulation of transcription by RNA polymerase II	TAS
GO:0001657	ureteric bud development	IEA
GO:0001701	in utero embryonic development	IEA
GO:0001706	endoderm formation	IEA
GO:0001707	mesoderm formation	ISS
GO:0007179	transforming growth factor beta receptor signaling pathway	IDA
GO:0007179	transforming growth factor beta receptor signaling pathway	IMP
GO:0007179	transforming growth factor beta receptor signaling pathway	TAS
GO:0007182	common-partner SMAD protein phosphorylation	IDA
GO:0007183	SMAD protein complex assembly	IDA
GO:0007352	zygotic specification of dorsal/ventral axis	IMP
GO:0007369	gastrulation	TAS
GO:0008285	negative regulation of cell population proliferation	IEA
GO:0009749	response to glucose	IEA
GO:0009791	post-embryonic development	IEA
GO:0009952	anterior/posterior pattern specification	ISS
GO:0010718	positive regulation of epithelial to mesenchymal transition	ISS
GO:0016579	protein deubiquitination	TAS
GO:0017015	regulation of transforming growth factor beta receptor signaling pathway	IMP
GO:0023019	signal transduction involved in regulation of gene expression	IEA
GO:0030073	insulin secretion	IEA
GO:0030324	lung development	IEA
GO:0030325	adrenal gland development	IEA
GO:0030512	negative regulation of transforming growth factor beta receptor signaling pathway	TAS
GO:0030513	positive regulation of BMP signaling pathway	IMP
GO:0031016	pancreas development	IEA
GO:0031053	primary miRNA processing	TAS
GO:0032924	activin receptor signaling pathway	IMP
GO:0035019	somatic stem cell population maintenance	TAS
GO:0035265	organ growth	IEA
GO:0035556	intracellular signal transduction	ISS
GO:0038092	nodal signaling pathway	IMP
GO:0042060	wound healing	IEA
GO:0045165	cell fate commitment	ISS
GO:0045892	negative regulation of transcription, DNA-templated	IMP
GO:0045893	positive regulation of transcription, DNA-templated	ISS
GO:0045893	positive regulation of transcription, DNA-templated	IMP
GO:0045893	positive regulation of transcription, DNA-templated	IDA
GO:0045944	positive regulation of transcription by RNA polymerase II	ISS
GO:0045944	positive regulation of transcription by RNA polymerase II	IDA
GO:0045944	positive regulation of transcription by RNA polymerase II	TAS
GO:0048340	paraxial mesoderm morphogenesis	ISS
GO:0048617	embryonic foregut morphogenesis	IEA
GO:0048701	embryonic cranial skeleton morphogenesis	IEA
GO:0051098	regulation of binding	ISS
GO:0060039	pericardium development	IEA
GO:0060395	SMAD protein signal transduction	IEA
GO:0062009	secondary palate development	ISS
GO:0070723	response to cholesterol	IDA
GO:1900224	positive regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry	IMP

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0000790	nuclear chromatin	ISA
GO:0000790	nuclear chromatin	IDA
GO:0005634	nucleus	IDA
GO:0005654	nucleoplasm	TAS
GO:0005667	transcription factor complex	IDA
GO:0005737	cytoplasm	IDA
GO:0005829	cytosol	TAS
GO:0032444	activin responsive factor complex	IDA
GO:0032991	protein-containing complex	IMP
GO:0071141	SMAD protein complex	IDA
GO:0071144	heteromeric SMAD protein complex	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1181150	Signaling by NODAL	IEA
R-HSA-1181150	Signaling by NODAL	TAS
R-HSA-1266738	Developmental Biology	IEA
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1502540	Signaling by Activin	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-1643685	Disease	TAS
R-HSA-170834	Signaling by TGF-beta Receptor Complex	TAS
R-HSA-170834	Signaling by TGF-beta Receptor Complex	IEA
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-212436	Generic Transcription Pathway	IEA
R-HSA-2173788	Downregulation of TGF-beta receptor signaling	TAS
R-HSA-2173789	TGF-beta receptor signaling activates SMADs	TAS
R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	TAS
R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	IEA
R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	TAS
R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	IEA
R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	TAS
R-HSA-3304347	Loss of Function of SMAD4 in Cancer	TAS
R-HSA-3304349	Loss of Function of SMAD2/3 in Cancer	TAS
R-HSA-3304351	Signaling by TGF-beta Receptor Complex in Cancer	TAS
R-HSA-3304356	SMAD2/3 Phosphorylation Motif Mutants in Cancer	TAS
R-HSA-3311021	SMAD4 MH2 Domain Mutants in Cancer	TAS
R-HSA-3315487	SMAD2/3 MH2 Domain Mutants in Cancer	TAS
R-HSA-3656532	TGFBR1 KD Mutants in Cancer	TAS
R-HSA-3656534	Loss of Function of TGFBR1 in Cancer	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-452723	Transcriptional regulation of pluripotent stem cells	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5688426	Deubiquitination	TAS
R-HSA-5689880	Ub-specific processing proteases	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-73857	RNA Polymerase II Transcription	IEA
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-74160	Gene expression (Transcription)	IEA
R-HSA-9006936	Signaling by TGF-beta family members	TAS
R-HSA-9006936	Signaling by TGF-beta family members	IEA
R-HSA-9614085	FOXO-mediated transcription	IEA
R-HSA-9614085	FOXO-mediated transcription	TAS
R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	IEA
R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	IEA
R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C504897	12-(3-adamantan-1-ylureido)dodecanoic acid	12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	28694203
C049325	1,2-dithiol-3-thione	1,2-dithiol-3-thione results in decreased expression of SMAD2 mRNA	19162173
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of SMAD2 protein modified form	21705713
C490166	1-(4-methoxyphenyl)piperazine	1-(4-methoxyphenyl)piperazine results in increased expression of SMAD2 mRNA	26821219
C097240	15-deoxy-delta(12,14)-prostaglandin J2	15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	19429239
C097240	15-deoxy-delta(12,14)-prostaglandin J2	SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]]	19429239
C072581	16-hydroxycleroda-3,13(14)-dien-15,16-olide	16-hydroxycleroda-3,13(14)-dien-15,16-olide results in decreased expression of SMAD2 protein	23628706
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in increased phosphorylation of SMAD2 protein	21037076
D015058	1-Naphthylisothiocyanate	F2R protein promotes the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of SMAD2 protein]	21037076
D015058	1-Naphthylisothiocyanate	F3 protein promotes the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of SMAD2 protein]	21037076
D015058	1-Naphthylisothiocyanate	[ITGA5 protein co-treated with ITGB6 protein] promotes the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of SMAD2 protein]	21037076
D015058	1-Naphthylisothiocyanate	TGFB1 protein promotes the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of SMAD2 protein]	21037076
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	25873302
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	25873302
C029497	2,3-bis(3'-hydroxybenzyl)butyrolactone	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SMAD2 mRNA	19167446
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of SMAD2 protein]	27856280
D015073	2-Acetylaminofluorene	[2-Acetylaminofluorene co-treated with Diethylnitrosamine] results in increased phosphorylation of SMAD2 protein	15368444
D015073	2-Acetylaminofluorene	IFNA2 protein promotes the reaction [[2-Acetylaminofluorene co-treated with Diethylnitrosamine] results in increased phosphorylation of SMAD2 protein]	15368444
D000077584	2-Methoxyestradiol	2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased phosphorylation of SMAD2 protein]	30154949
C047368	3-methylquercetin	3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	27151496
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide affects the phosphorylation of SMAD2 protein	22363485
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Etoposide results in increased phosphorylation of SMAD2 protein]	22363485
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein]	20458730
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [INHBA protein results in increased phosphorylation of SMAD2 protein]	20074812
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Melphalan results in increased phosphorylation of SMAD2 protein]	22363485
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	31381904
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]	21520325
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased expression of HAS2 mRNA]	21520325
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased expression of TNFAIP6 mRNA]	21520325
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] promotes the reaction [FSHB protein results in increased chemical synthesis of Progesterone]	21520325
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] which co-treated with FSHB protein] results in increased expression of PTX3 mRNA	21520325
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] which results in decreased susceptibility to FSHB protein	21520325
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of and results in increased localization of SMAD2 protein]	20852150
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased phosphorylation of SMAD2 protein	20852150
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Carbofuran results in increased phosphorylation of SMAD2 protein]	28982980
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased phosphorylation of SMAD2 protein	28982980
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of SMAD2 protein	21520325
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [EGF protein results in increased chemical synthesis of Hyaluronic Acid]	21520325
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] which results in decreased susceptibility to EGF protein	21520325
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SMAD2 mRNA	19150397
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of SMAD2 mRNA	28529061
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of SMAD2 protein	28529061
D000082	Acetaminophen	Acetaminophen results in decreased expression of SMAD2 mRNA	16701773
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with sodium arsenite] results in increased expression of SMAD2 mRNA]	29408318
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	30317545
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [Water Pollutants, Chemical results in increased expression of SMAD2 mRNA]	29408318
C058956	acteoside	acteoside results in increased phosphorylation of SMAD2 protein	17634406
D000077410	Aluminum Chloride	Aluminum Chloride inhibits the reaction [SMAD2 protein binds to SMAD3 protein binds to SMAD4 protein]	26658030
D000077410	Aluminum Chloride	Aluminum Chloride results in decreased expression of [SMAD2 protein binds to SMAD3 protein binds to SMAD4 protein]	27720690
D000077410	Aluminum Chloride	TGFB1 protein inhibits the reaction [Aluminum Chloride results in decreased expression of [SMAD2 protein binds to SMAD3 protein binds to SMAD4 protein]]	27720690
D017311	Amlodipine	Amlodipine inhibits the reaction [[Doxorubicin co-treated with TGFB1 protein] results in increased phosphorylation of SMAD2 protein]	21337027
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of SMAD2 mRNA	16483693
D000872	Anthocyanins	Anthocyanins inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	30403199
D000952	Antigens, Polyomavirus Transforming	Antigens, Polyomavirus Transforming results in increased expression of SMAD2 mRNA	26680231
D018501	Antirheumatic Agents	Antirheumatic Agents results in increased expression of SMAD2 mRNA	24449571
D001149	Arsenates	[Atrazine co-treated with Arsenates] results in increased expression of SMAD2 mRNA	18585445
D001151	Arsenic	Arsenic results in increased expression of SMAD2 protein modified form	24348802
D001151	Arsenic	Grape Seed Extract inhibits the reaction [Arsenic results in increased expression of SMAD2 protein modified form]	24348802
D000077237	Arsenic Trioxide	Arsenic Trioxide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	24762191; 30317545;
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of SMAD2 mRNA	25258189
C015001	arsenite	arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]	26354774
C015001	arsenite	arsenite inhibits the reaction [TGFB2 protein results in increased localization of SMAD2 protein]	25145660
C015001	arsenite	arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]	26354774
C015001	arsenite	leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C015001	arsenite	leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]	26354774
C015001	arsenite	Zinc inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
D001194	Asbestos	[Asbestos, Serpentine results in decreased susceptibility to Asbestos] which results in increased expression of SMAD2 mRNA	25358858
D001194	Asbestos	[Asbestos, Serpentine results in decreased susceptibility to Asbestos] which results in increased phosphorylation of SMAD2 protein	25358858
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite affects the expression of SMAD2 mRNA	17331233
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased phosphorylation of SMAD2 protein	17975199
D017632	Asbestos, Serpentine	Asbestos, Serpentine affects the localization of SMAD2 protein modified form	26685284
D017632	Asbestos, Serpentine	[Asbestos, Serpentine results in decreased susceptibility to Asbestos] which results in increased expression of SMAD2 mRNA	25358858
D017632	Asbestos, Serpentine	[Asbestos, Serpentine results in decreased susceptibility to Asbestos] which results in increased phosphorylation of SMAD2 protein	25358858
D001280	Atrazine	[Atrazine co-treated with Arsenates] results in increased expression of SMAD2 mRNA	18585445
C044946	benazepril	benazepril affects the expression of SMAD2 mRNA	16635409
C044946	benazepril	benazepril affects the expression of SMAD2 protein	16635409
C044946	benazepril	[benazepril co-treated with Irbesartan] affects the expression of SMAD2 mRNA	16635409
C044946	benazepril	[benazepril co-treated with Irbesartan] affects the expression of SMAD2 protein	16635409
D001688	Biological Products	Biological Products results in decreased expression of SMAD2 mRNA	23624380
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein]	22155090
C006780	bisphenol A	bisphenol A affects the expression of SMAD2 mRNA	21786754
C006780	bisphenol A	bisphenol A results in increased expression of SMAD2 mRNA	29027980
C006780	bisphenol A	bisphenol A results in increased methylation of SMAD2 promoter	27271280
C006780	bisphenol A	bisphenol A affects the methylation of SMAD2 promoter	27334623
C006780	bisphenol A	bisphenol A affects the expression of SMAD2 mRNA	25181051
C018475	butyraldehyde	butyraldehyde results in decreased expression of SMAD2 mRNA	26079696
D019256	Cadmium Chloride	Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with sodium arsenite] results in increased expression of SMAD2 mRNA]	29408318
D019256	Cadmium Chloride	[Cadmium Chloride co-treated with sodium arsenite] results in increased expression of SMAD2 mRNA	29408318
D002235	Carbofuran	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Carbofuran results in increased phosphorylation of SMAD2 protein]	28982980
D002235	Carbofuran	Carbofuran results in increased expression of SMAD2 mRNA	28982980
D002235	Carbofuran	Carbofuran results in increased phosphorylation of SMAD2 protein	28982980
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of SMAD2 protein modified form	25566828
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of SMAD2 mRNA	26297989
D002251	Carbon Tetrachloride	chrysin inhibits the reaction [Carbon Tetrachloride results in increased expression of SMAD2 mRNA]	26297989
D002251	Carbon Tetrachloride	Silymarin inhibits the reaction [Carbon Tetrachloride results in increased expression of SMAD2 mRNA]	26297989
D002251	Carbon Tetrachloride	SMAD2 protein affects the susceptibility to Carbon Tetrachloride	16382155
D002251	Carbon Tetrachloride	[Carbon Tetrachloride co-treated with Ethanol] results in increased phosphorylation of SMAD2 protein	30543783
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of SMAD2 mRNA	16570350
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased phosphorylation of SMAD2 protein	24211420; 25150141;
D002251	Carbon Tetrachloride	methyl ferulate inhibits the reaction [[Carbon Tetrachloride co-treated with Ethanol] results in increased phosphorylation of SMAD2 protein]	30543783
D002336	Carnosine	Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of SMAD2 protein]	28266762
D002791	Cholesterol, Dietary	Cholesterol, Dietary results in increased expression of SMAD2 mRNA	27239252
D002791	Cholesterol, Dietary	Rutin inhibits the reaction [Cholesterol, Dietary results in increased expression of SMAD2 mRNA]	27239252
D002857	Chromium	Chromium results in increased expression of SMAD2 mRNA	17692352
C043561	chrysin	chrysin inhibits the reaction [Carbon Tetrachloride results in increased expression of SMAD2 mRNA]	26297989
C012843	cinnamic aldehyde	cinnamic aldehyde results in increased expression of SMAD2 mRNA	19524605
D002945	Cisplatin	Cisplatin results in decreased expression of SMAD2 protein	23628706
D002994	Clofibrate	Clofibrate results in increased expression of SMAD2 mRNA	22300585
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of SMAD2 mRNA	19320972; 19376846;
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of SMAD2 mRNA	19789285
D019327	Copper Sulfate	Copper Sulfate results in increased expression of SMAD2 mRNA	19789285
D003345	Corticosterone	Corticosterone results in decreased expression of SMAD2 mRNA	29660438
D003375	Coumestrol	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SMAD2 mRNA	19167446
C057862	cyanoginosin LR	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of SMAD2 protein]	27856280
C057862	cyanoginosin LR	cyanoginosin LR results in increased expression of and results in increased phosphorylation of SMAD2 protein	27856280
C057862	cyanoginosin LR	SMAD2 protein affects the reaction [cyanoginosin LR results in decreased expression of CDH1 protein]	27856280
C057862	cyanoginosin LR	SMAD2 protein affects the reaction [cyanoginosin LR results in increased expression of SNAI1 protein]	27856280
C057862	cyanoginosin LR	SMAD2 protein affects the reaction [cyanoginosin LR results in increased expression of VIM protein]	27856280
D016572	Cyclosporine	bisindolylmaleimide I inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein]	22155090
D016572	Cyclosporine	Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein	22155090
D016572	Cyclosporine	hispidin inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein]	22155090
D016572	Cyclosporine	salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein]	22155090
D015638	Cytochalasin D	Cytochalasin D affects the localization of SMAD2 protein	25756282
D000077209	Decitabine	Decitabine results in increased expression of SMAD2 mRNA	27915011
D000077209	Decitabine	Decitabine inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	24211420
D003907	Dexamethasone	Dexamethasone results in decreased expression of SMAD2 mRNA	29329878
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of SMAD2 mRNA	26924002
D004052	Diethylnitrosamine	[2-Acetylaminofluorene co-treated with Diethylnitrosamine] results in increased phosphorylation of SMAD2 protein	15368444
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased phosphorylation of SMAD2 protein	18971187
D004052	Diethylnitrosamine	IFNA2 protein promotes the reaction [[2-Acetylaminofluorene co-treated with Diethylnitrosamine] results in increased phosphorylation of SMAD2 protein]	15368444
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased phosphorylation of SMAD2 protein	17255206
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in increased phosphorylation of SMAD2 protein	14568256
D004128	Dimethylnitrosamine	Leu-Ser-Lys-Leu peptide inhibits the reaction [Dimethylnitrosamine results in increased phosphorylation of SMAD2 protein]	14568256
C024629	dimethyl phthalate	dimethyl phthalate results in increased expression of SMAD2 mRNA	26924002
C516138	dorsomorphin	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
D004317	Doxorubicin	Amlodipine inhibits the reaction [[Doxorubicin co-treated with TGFB1 protein] results in increased phosphorylation of SMAD2 protein]	21337027
D004317	Doxorubicin	[Doxorubicin co-treated with TGFB1 protein] results in increased expression of SMAD2 mRNA	21337027
D004317	Doxorubicin	[Doxorubicin co-treated with TGFB1 protein] results in increased expression of SMAD2 protein	21337027
D004317	Doxorubicin	[Doxorubicin co-treated with TGFB1 protein] results in increased phosphorylation of SMAD2 protein	21337027
D004317	Doxorubicin	Doxorubicin results in decreased expression of SMAD2 protein	18606404
D004317	Doxorubicin	Doxorubicin results in increased expression of SMAD2 mRNA	21337027
D060766	Drinking Water	Drinking Water results in decreased expression of SMAD2 mRNA	19444861
D004656	Enalapril	Enalapril promotes the reaction [paricalcitol results in decreased phosphorylation of SMAD2 protein]	17513326
D004726	Endosulfan	Endosulfan results in decreased expression of SMAD2 mRNA	30090376
C118739	entinostat	entinostat results in decreased expression of SMAD2 mRNA	26272509
C118739	entinostat	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
D004958	Estradiol	Estradiol results in decreased phosphorylation of SMAD2 protein	17255206
D000431	Ethanol	[Carbon Tetrachloride co-treated with Ethanol] results in increased phosphorylation of SMAD2 protein	30543783
D000431	Ethanol	Ethanol results in decreased expression of SMAD2 mRNA	17920746
D000431	Ethanol	methyl ferulate inhibits the reaction [[Carbon Tetrachloride co-treated with Ethanol] results in increased phosphorylation of SMAD2 protein]	30543783
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of SMAD2 mRNA	17606305
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SMAD2 mRNA	17942748
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of SMAD2 gene	16724327
D005047	Etoposide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Etoposide results in increased phosphorylation of SMAD2 protein]	22363485
D005047	Etoposide	Etoposide results in increased phosphorylation of SMAD2 protein	22363485
D005688	Galactosamine	Galactosamine results in increased phosphorylation of SMAD2 protein	27876602
D005688	Galactosamine	Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein]	27876602
C037032	galangin	galangin results in increased expression of SMAD2 mRNA	25268046
C037032	galangin	galangin results in increased phosphorylation of SMAD2 protein	25268046
C037032	galangin	LY2109761 inhibits the reaction [galangin results in increased phosphorylation of SMAD2 protein]	25268046
D019833	Genistein	Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein]	27876602
D005839	Gentamicins	Gentamicins results in increased expression of SMAD2 mRNA	22061828
C097367	ginsenoside Rg3	ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	24793912
C055124	glaucocalyxin A	glaucocalyxin A inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	31059706
D005944	Glucosamine	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein]	20458730
D005944	Glucosamine	Glucosamine analog results in increased phosphorylation of SMAD2 protein	20458730
D005947	Glucose	Glucose results in increased phosphorylation of and affects the localization of SMAD2 protein	17597607
D005947	Glucose	Glucose results in increased phosphorylation of SMAD2 protein	21367880
D005947	Glucose	isoangustone A inhibits the reaction [Glucose results in increased phosphorylation of SMAD2 protein]	21367880
D005947	Glucose	protocatechualdehyde inhibits the reaction [Glucose results in increased phosphorylation of and affects the localization of SMAD2 protein]	17597607
C010974	glyphosate	[Surface-Active Agents co-treated with glyphosate] results in increased expression of SMAD2 mRNA	22467014
D056604	Grape Seed Extract	Grape Seed Extract inhibits the reaction [Arsenic results in increased expression of SMAD2 protein modified form]	24348802
D056604	Grape Seed Extract	Grape Seed Extract inhibits the reaction [sodium arsenite results in increased phosphorylation of SMAD2 protein]	21605584
C007946	hispidin	hispidin inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein]	22155090
C005499	honokiol	honokiol inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	21265825
D006820	Hyaluronic Acid	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]	21520325
D006820	Hyaluronic Acid	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [EGF protein results in increased chemical synthesis of Hyaluronic Acid]	21520325
D006861	Hydrogen Peroxide	[Hydrogen Peroxide co-treated with Theophylline] results in increased expression of SMAD2 protein	18951874
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased phosphorylation of SMAD2 protein	15147944
D000077405	Irbesartan	[benazepril co-treated with Irbesartan] affects the expression of SMAD2 mRNA	16635409
D000077405	Irbesartan	[benazepril co-treated with Irbesartan] affects the expression of SMAD2 protein	16635409
D000077405	Irbesartan	Irbesartan affects the expression of SMAD2 mRNA	16635409
D000077405	Irbesartan	Irbesartan affects the expression of SMAD2 protein	16635409
C551631	isoangustone A	isoangustone A inhibits the reaction [Glucose results in increased phosphorylation of SMAD2 protein]	21367880
D019344	Lactic Acid	Lactic Acid results in increased expression of SMAD2 mRNA	30851411
C038753	leptomycin B	leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C038753	leptomycin B	leptomycin B inhibits the reaction [arsenite inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]	26354774
C038753	leptomycin B	leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C038753	leptomycin B	leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]	26354774
C487834	Leu-Ser-Lys-Leu peptide	Leu-Ser-Lys-Leu peptide inhibits the reaction [Dimethylnitrosamine results in increased phosphorylation of SMAD2 protein]	14568256
C440499	lipopolysaccharide, Escherichia coli O111 B4	lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of SMAD2 protein	25234611
C440499	lipopolysaccharide, Escherichia coli O111 B4	Resveratrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of SMAD2 protein]	25234611
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of SMAD2 mRNA	10975854
D008070	Lipopolysaccharides	Lipopolysaccharides promotes the reaction [Thioacetamide results in increased expression of SMAD2 mRNA]	17621560
D018021	Lithium Chloride	Lithium Chloride results in decreased expression of SMAD2 mRNA	17506889
C530108	LY2109761	LY2109761 inhibits the reaction [galangin results in increased phosphorylation of SMAD2 protein]	25268046
C530108	LY2109761	LY2109761 inhibits the reaction [TGFB1 protein results in increased expression of SMAD2 protein modified form]	30008374
C530108	LY2109761	LY2109761 results in decreased expression of SMAD2 protein modified form	30008374
C557799	LY-2157299	[ABCB4 protein affects the susceptibility to LY-2157299] which affects the phosphorylation of SMAD2 protein	29808285
C520284	Ly-364947	Ly-364947 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	24727557
C520284	Ly-364947	Ly-364947 inhibits the reaction [TGFB3 protein results in increased expression of SMAD2 protein modified form]	25566828
C520284	Ly-364947	Ly-364947 results in decreased expression of SMAD2 protein modified form	25566828
D008558	Melphalan	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Melphalan results in increased phosphorylation of SMAD2 protein]	22363485
D008558	Melphalan	Melphalan results in increased phosphorylation of SMAD2 protein	22363485
D008628	Mercury	Mercury results in increased expression of SMAD2 mRNA	19937285
C014085	methotrexate polyglutamate	SMAD2 gene affects the abundance of methotrexate polyglutamate	19066393
D008731	Methoxychlor	Methoxychlor results in decreased expression of SMAD2 mRNA	23303685
D008731	Methoxychlor	Methoxychlor results in increased methylation of SMAD2 gene	23303685
C005219	methyl cellosolve	methyl cellosolve results in increased expression of SMAD2 mRNA	21061450
C530806	methyl ferulate	methyl ferulate inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	30543783
C530806	methyl ferulate	methyl ferulate inhibits the reaction [[Carbon Tetrachloride co-treated with Ethanol] results in increased phosphorylation of SMAD2 protein]	30543783
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of SMAD2 mRNA	28001369
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of SMAD2 mRNA	23649840
D008769	Methylnitronitrosoguanidine	Methylnitronitrosoguanidine results in decreased expression of SMAD2 mRNA	12634122
D008942	Mitoxantrone	SMAD2 protein affects the susceptibility to Mitoxantrone	16217747
C406082	monomethylarsonous acid	leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C406082	monomethylarsonous acid	leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]]	26354774
C406082	monomethylarsonous acid	monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]	26354774
C406082	monomethylarsonous acid	monomethylarsonous acid inhibits the reaction [TGFB2 protein results in increased localization of SMAD2 protein]	25145660
C406082	monomethylarsonous acid	monomethylarsonous acid inhibits the reaction [XPO4 protein results in increased export of SMAD2 protein]	26354774
C406082	monomethylarsonous acid	monomethylarsonous acid results in decreased activity of SMAD2 protein	25145660
C406082	monomethylarsonous acid	Zinc inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of SMAD2 mRNA	26924002
D009538	Nicotine	Nicotine results in decreased expression of SMAD2 mRNA	29660438; 31299270;
D009538	Nicotine	Nicotine results in decreased expression of SMAD2 protein	29660438; 31299270;
C007350	nitrofen	nitrofen results in decreased expression of SMAD2 mRNA	12149686
C011959	oridonin	oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	30243739
C046627	osthol	[platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	23603464
C046627	osthol	[platycodin D co-treated with osthol] results in decreased expression of SMAD2 mRNA	23603464
C046627	osthol	[platycodin D co-treated with osthol] results in decreased expression of SMAD2 protein	23603464
D010100	Oxygen	Oxygen deficiency results in increased phosphorylation of SMAD2 protein	23725749
D010100	Oxygen	Oxygen deficiency results in increased phosphorylation of SMAD2 protein	21531777
D010100	Oxygen	Rosiglitazone inhibits the reaction [Oxygen deficiency results in increased phosphorylation of SMAD2 protein]	21531777
D000077767	Panobinostat	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
D000077767	Panobinostat	Panobinostat results in decreased expression of SMAD2 mRNA	26272509
D010269	Paraquat	Paraquat results in increased expression of SMAD2 protein modified form	27682480
D010269	Paraquat	TGFB1 protein promotes the reaction [Paraquat results in increased expression of SMAD2 protein modified form]	27682480
D010269	Paraquat	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	25873302
D010269	Paraquat	Anthocyanins inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	30403199
D010269	Paraquat	Paraquat results in increased phosphorylation of SMAD2 protein	25873302; 30403199;
D010269	Paraquat	[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	25873302
D010269	Paraquat	SB 203580 inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	25873302
C084656	paricalcitol	Enalapril promotes the reaction [paricalcitol results in decreased phosphorylation of SMAD2 protein]	17513326
C084656	paricalcitol	paricalcitol results in decreased phosphorylation of SMAD2 protein	17513326
D010416	Pentachlorophenol	Pentachlorophenol results in increased expression of SMAD2 mRNA	24642059
D010634	Phenobarbital	Phenobarbital affects the expression of SMAD2 mRNA	19159669
D010656	Phenylephrine	Phenylephrine results in increased phosphorylation of and results in increased localization of and results in increased activity of SMAD2 protein	19443575
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of SMAD2 mRNA	26272509
D010696	Phloroglucinol	Phloroglucinol analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	26054450
D010795	Phthalic Acids	Phthalic Acids results in increased expression of SMAD2 mRNA	21061450
C108953	platycodin D	[platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	23603464
C108953	platycodin D	[platycodin D co-treated with osthol] results in decreased expression of SMAD2 mRNA	23603464
C108953	platycodin D	[platycodin D co-treated with osthol] results in decreased expression of SMAD2 protein	23603464
C035988	procymidone	procymidone results in decreased expression of SMAD2 mRNA	15686871
D011374	Progesterone	[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] promotes the reaction [FSHB protein results in increased chemical synthesis of Progesterone]	21520325
D011374	Progesterone	Progesterone affects the expression of SMAD2 mRNA	17251523
C005581	protocatechualdehyde	protocatechualdehyde inhibits the reaction [Glucose results in increased phosphorylation of and affects the localization of SMAD2 protein]	17597607
C005581	protocatechualdehyde	protocatechualdehyde inhibits the reaction [S100B protein results in increased phosphorylation of and affects the localization of SMAD2 protein]	17597607
D011794	Quercetin	Quercetin inhibits the reaction [SMAD2 protein modified form binds to SMAD3 protein modified form binds to SMAD4 protein]	15580028
D011794	Quercetin	Quercetin results in decreased expression of SMAD2 protein	15580028
D011794	Quercetin	Quercetin results in decreased expression of SMAD2 protein modified form	15580028
D011794	Quercetin	Quercetin promotes the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	21216973
D011794	Quercetin	Quercetin inhibits the reaction [Sodium Nitrite results in increased expression of SMAD2 protein]	28000380
D000077185	Resveratrol	Resveratrol results in decreased expression of SMAD2 mRNA	18089832; 25721869;
D000077185	Resveratrol	Resveratrol results in decreased expression of SMAD2 protein	18089832; 25721869;
D000077185	Resveratrol	Resveratrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of SMAD2 protein]	25234611
D000077185	Resveratrol	Resveratrol results in decreased phosphorylation of SMAD2 protein	21679764
D000077185	Resveratrol	Resveratrol inhibits the reaction [Streptozocin results in increased phosphorylation of SMAD2 protein]	21300041
D000077154	Rosiglitazone	Rosiglitazone inhibits the reaction [Oxygen deficiency results in increased phosphorylation of SMAD2 protein]	21531777
D012431	Rutin	Rutin inhibits the reaction [Cholesterol, Dietary results in increased expression of SMAD2 mRNA]	27239252
C496827	salubrinal	salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein]	22155090
C410958	sauchinone	sauchinone inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	25451574
C093642	SB 203580	[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	25873302
C093642	SB 203580	SB 203580 inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]	25873302
D012835	Silver Nitrate	Silver Nitrate analog results in decreased expression of SMAD2 mRNA	22831968
D012835	Silver Nitrate	Silver Nitrate results in increased expression of SMAD2 mRNA	22831968
D012838	Silymarin	Silymarin inhibits the reaction [Carbon Tetrachloride results in increased expression of SMAD2 mRNA]	26297989
D019821	Simvastatin	Simvastatin results in increased expression of SMAD2 mRNA	18310456
D019821	Simvastatin	Simvastatin results in decreased phosphorylation of SMAD2 protein	19659652
C017947	sodium arsenite	Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with sodium arsenite] results in increased expression of SMAD2 mRNA]	29408318
C017947	sodium arsenite	[Cadmium Chloride co-treated with sodium arsenite] results in increased expression of SMAD2 mRNA	29408318
C017947	sodium arsenite	sodium arsenite results in decreased expression of SMAD2 mRNA	29301061
C017947	sodium arsenite	sodium arsenite affects the expression of and affects the phosphorylation of SMAD2 protein	28206643
C017947	sodium arsenite	sodium arsenite inhibits the reaction [TGFB2 protein results in increased phosphorylation of and affects the localization of SMAD2 protein]	23732083
C017947	sodium arsenite	sodium arsenite results in decreased phosphorylation of SMAD2 protein	23732083
C017947	sodium arsenite	Grape Seed Extract inhibits the reaction [sodium arsenite results in increased phosphorylation of SMAD2 protein]	21605584
C017947	sodium arsenite	sodium arsenite results in increased phosphorylation of SMAD2 protein	21605584
D012977	Sodium Nitrite	Carnosine inhibits the reaction [Sodium Nitrite results in increased expression of SMAD2 protein]	28266762
D012977	Sodium Nitrite	Quercetin inhibits the reaction [Sodium Nitrite results in increased expression of SMAD2 protein]	28000380
D012977	Sodium Nitrite	Sodium Nitrite results in increased expression of SMAD2 protein	28000380; 28266762;
D012999	Soman	Soman results in increased expression of SMAD2 mRNA	19281266
D053260	Soot	Soot results in decreased expression of SMAD2 mRNA	23634900
D000077157	Sorafenib	Sorafenib affects the localization of SMAD2 protein	21360571
D000077157	Sorafenib	Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	21360571
D013311	Streptozocin	Resveratrol inhibits the reaction [Streptozocin results in increased phosphorylation of SMAD2 protein]	21300041
D013311	Streptozocin	Streptozocin results in increased phosphorylation of SMAD2 protein	21300041
D000077210	Sunitinib	Sunitinib results in increased expression of SMAD2 mRNA	31533062
D013501	Surface-Active Agents	[Surface-Active Agents co-treated with glyphosate] results in increased expression of SMAD2 mRNA	22467014
C061133	tamibarotene	tamibarotene results in decreased expression of SMAD2 mRNA	15498508
C061133	tamibarotene	tamibarotene results in increased phosphorylation of SMAD2 protein	17611697
D013629	Tamoxifen	Tamoxifen promotes the reaction [Tretinoin results in increased phosphorylation of SMAD2 protein]	17098229
D013629	Tamoxifen	Tamoxifen results in increased phosphorylation of SMAD2 protein	17098229
C004648	testosterone enanthate	2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased phosphorylation of SMAD2 protein]	30154949
C004648	testosterone enanthate	testosterone enanthate results in increased phosphorylation of SMAD2 protein	30154949
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of SMAD2 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SMAD2 mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased activity of SMAD2 protein	18467041
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SMAD2 mRNA	24058054
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SMAD2 protein	18467041
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin results in increased expression of TGFB1 protein] which results in increased activity of SMAD2 protein	18467041
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased expression of and affects the localization of SMAD2 protein	20172950
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of SMAD2 protein	20172950
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased expression of SMAD2 protein	20172950
D013755	Tetradecanoylphorbol Acetate	TGFB1 affects the reaction [Tetradecanoylphorbol Acetate results in increased expression of and affects the localization of SMAD2 protein]	20172950
D013755	Tetradecanoylphorbol Acetate	TGFB1 affects the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of SMAD2 protein]	20172950
D013755	Tetradecanoylphorbol Acetate	TGFB1 affects the reaction [Tetradecanoylphorbol Acetate results in increased expression of SMAD2 protein]	20172950
D013755	Tetradecanoylphorbol Acetate	TGFB1 promotes the reaction [Tetradecanoylphorbol Acetate affects the localization of SMAD2 protein modified form]	20172950
D013806	Theophylline	[Hydrogen Peroxide co-treated with Theophylline] results in increased expression of SMAD2 protein	18951874
D013853	Thioacetamide	Lipopolysaccharides promotes the reaction [Thioacetamide results in increased expression of SMAD2 mRNA]	17621560
D013853	Thioacetamide	Thioacetamide results in increased expression of SMAD2 mRNA	17621560; 23411599;
D013893	Thiram	Thiram results in decreased expression of SMAD2 mRNA	20530235
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased localization of SMAD2 protein	15994428
C009500	tolfenamic acid	tolfenamic acid inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]	31381904
D014212	Tretinoin	Tamoxifen promotes the reaction [Tretinoin results in increased phosphorylation of SMAD2 protein]	17098229
D014212	Tretinoin	Tretinoin inhibits the reaction [TGFB1 results in increased phosphorylation of and results in increased localization of SMAD2 protein]	21274875
D014212	Tretinoin	Tretinoin results in decreased expression of SMAD2 mRNA	15498508
D014212	Tretinoin	Tretinoin results in decreased phosphorylation of SMAD2 protein	24374174
D014212	Tretinoin	Tretinoin results in increased phosphorylation of SMAD2 protein	17098229
D014212	Tretinoin	Tretinoin results in decreased expression of SMAD2 mRNA	18703560
D014212	Tretinoin	Tretinoin results in decreased phosphorylation of SMAD2 protein	16410076
D014241	Trichloroethylene	Trichloroethylene results in increased expression of SMAD2 mRNA	19448997
C012589	trichostatin A	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
C012589	trichostatin A	trichostatin A results in decreased expression of SMAD2 mRNA	24935251; 26272509;
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB2 protein results in increased phosphorylation of and affects the localization of SMAD2 protein]	18253093
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB1 protein results in increased expression of SMAD2 protein]	19120328
D014635	Valproic Acid	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of SMAD2 mRNA	23179753; 25979313;
D014635	Valproic Acid	Valproic Acid results in decreased expression of SMAD2 mRNA	24383497; 26272509; 27188386;
D014635	Valproic Acid	Valproic Acid results in increased methylation of SMAD2 gene	29154799
D014635	Valproic Acid	Valproic Acid results in decreased expression of SMAD2 mRNA	21427059
D014640	Vancomycin	Vancomycin results in decreased expression of SMAD2 mRNA	18930951
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of SMAD2 gene	25560391
C025643	vinclozolin	vinclozolin results in decreased expression of SMAD2 mRNA	15686871
D014750	Vincristine	Vincristine results in decreased expression of SMAD2 mRNA	23649840
D000077337	Vorinostat	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMAD2 mRNA	27188386
D000077337	Vorinostat	Vorinostat results in decreased expression of SMAD2 mRNA	26272509
D014873	Water Pollutants	Water Pollutants results in decreased expression of SMAD2 mRNA	23591932
D014873	Water Pollutants	Water Pollutants results in decreased expression of SMAD2 protein	23591932
D014874	Water Pollutants, Chemical	Acetylcysteine inhibits the reaction [Water Pollutants, Chemical results in increased expression of SMAD2 mRNA]	29408318
D014874	Water Pollutants, Chemical	Water Pollutants, Chemical results in increased expression of SMAD2 mRNA	29408318
C521629	Wen-pi-tang-Hab-Wu-ling-san	Wen-pi-tang-Hab-Wu-ling-san affects the phosphorylation of SMAD2 protein	19913069
C000588914	WJ1376-1	WJ1376-1 inhibits the reaction [TGFB1 protein results in increased activity of SMAD2 protein]	24727557
C000588914	WJ1376-1	WJ1376-1 inhibits the reaction [TGFB1 protein results in increased phosphorylation of and affects the localization of SMAD2 protein]	24727557
C000588915	WJ1398-1	WJ1398-1 inhibits the reaction [TGFB1 protein results in increased activity of SMAD2 protein]	24727557
C000588915	WJ1398-1	WJ1398-1 inhibits the reaction [TGFB1 protein results in increased phosphorylation of and affects the localization of SMAD2 protein]	24727557
D015032	Zinc	Zinc inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
D015032	Zinc	Zinc inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
D015032	Zinc	Zinc promotes the reaction [SMAD3 protein modified form binds to SMAD2 protein modified form binds to NFIC protein]	22228435
D015032	Zinc	Zinc results in increased stability of and results in increased activity of SMAD2 protein	26354774

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0007	Acetylation
KW-0025	Alternative splicing
KW-0963	Cytoplasm
KW-0903	Direct protein sequencing
KW-0238	DNA-binding
KW-0479	Metal-binding
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0804	Transcription
KW-0805	Transcription regulation
KW-0832	Ubl conjugation
KW-0862	Zinc

Interpro

InterPro ID	InterPro Term
IPR013790	Dwarfin
IPR003619	MAD_homology1_Dwarfin-type
IPR013019	MAD_homology_MH1
IPR017855	SMAD-like_dom_sf
IPR001132	SMAD_dom_Dwarfin-type
IPR008984	SMAD_FHA_dom_sf
IPR036578	SMAD_MH1_sf

PROSITE

PROSITE ID	PROSITE Term
PS51075	MH1
PS51076	MH2

Pfam

Pfam ID	Pfam Term
PF03165	MH1
PF03166	MH2

Gene: SMAD2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Identified variants/mutations related to cleft phenotype

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction